---
schema_version: "secwatch.filing_event.v1"
accession: "0001600620-23-000030"
form_type: "8-K"
ticker: "AUPH"
cik: "0001600620"
company_name: "Aurinia Pharmaceuticals Inc."
filed_at: "2023-08-21T23:59:59+00:00"
generated_at: "2026-06-11T06:15:12.109307+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aurinia appoints Dr. Karen Smith and Jeffrey A. Bailey to Board; Dr. Daniel G. Billen named Chair

## Summary
- Dr. Karen Smith and Jeffrey A. Bailey joined Aurinia's Board effective August 18, 2023, bringing decades of biopharma leadership experience.
- Dr. Daniel G. Billen, board member since 2019, appointed Chair of the Board of Directors.
- Both new directors have experience with successful sales, mergers, and partnerships, relevant to the ongoing strategic review process.
- Dr. Smith has served on boards of several acquired companies (Forward Pharma, Sucampo, Acceleron, Antares Pharma).
- Mr. Bailey has held CEO and Chairman roles, including Chairman of Tekla Capital Management since 2020.

## SEC filing metadata
- accession: 0001600620-23-000030
- form_type: 8-K
- ticker: AUPH
- cik: 0001600620
- company_name: Aurinia Pharmaceuticals Inc.
- filed_at: 2023-08-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1600620/000160062023000030/0001600620-23-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1600620/000160062023000030/auph-20230818.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001600620-23-000030
- JSON: https://secwatch.observer/filing/0001600620-23-000030.json
- Plain text: https://secwatch.observer/filing/0001600620-23-000030.txt

## Key facts
- Executive change
  Jeffrey A. Bailey was appointed as Director at Aurinia Pharmaceuticals Inc..
  - Action: appointed
  - Role: Director
  source text: On August 21, 2023, Aurinia Pharmaceuticals Inc. (the Company) issued a press release announcing the appointments of Dr. Karen Smith and Jeffrey A. Bailey to the Board of Directors of the Company (the Board) effective August 18, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1600620/000160062023000030/0001600620-23-000030-index.htm
- Executive change
  Dr. Karen Smith was appointed as Director at Aurinia Pharmaceuticals Inc..
  - Action: appointed
  - Role: Director
  source text: On August 21, 2023, Aurinia Pharmaceuticals Inc. (the Company) issued a press release announcing the appointments of Dr. Karen Smith and Jeffrey A. Bailey to the Board of Directors of the Company (the Board) effective August 18, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1600620/000160062023000030/0001600620-23-000030-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.